donor-derived anti-leukemia cytotoxic T lymphocytes
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for donor-derived anti-leukemia cytotoxic T lymphocytes, covering 2025-03-07 to 2025-03-07. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation [Phase 1, Phase 2]